Comprehensive support for health promotion and drug discovery research through biological resources and genetic information
First written in FY2016. 24 of 27 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Under its corporate philosophy of contributing to the future and helping realize the health and enriched lives of people worldwide, the Group's basic management policy is to achieve growth and expansion by responding swiftly to changes in the business environment and appropriately adapting its business model and structure.」
This reconfirms the corporate philosophy of contributing to health and enriched lives and the basic policy of adapting the business model and structure to changes in the business environment. - FY2026-H1RestatedAnnual report
「The Group operates end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies and clinical trials.」
This reconfirms the positioning of the drug discovery support business as providing end-to-end support from exploratory basic research and drug discovery research through nonclinical and clinical trials. - FY2025-H1RestatedAnnual report
「The Group operates end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies and clinical trials.」
This reconfirms the positioning of the drug discovery support business as providing end-to-end support from exploratory basic research and drug discovery research through nonclinical and clinical trials. - FY2024ReframedAnnual report
「Under its corporate philosophy of contributing to the future and helping realize the health and enriched lives of people worldwide, the Group's basic management policy is to achieve growth and expansion by responding swiftly to changes in the business environment and appropriately adapting its business model and structure.」
While maintaining its corporate philosophy of contributing to health and enriched lives, the emphasis of the basic policy has shifted from positioning the Group as a comprehensive drug discovery support company to achieving Group growth by adapting its business model and structure to changes in the business environment. - FY2024-Q3RestatedAnnual report
「The Group operates end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies and clinical trials.」
This reconfirms the positioning of the drug discovery support business as providing end-to-end support from exploratory basic research and drug discovery research through nonclinical and clinical trials. - FY2024-Q2RestatedAnnual report
「The Group operates end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies and clinical trials.」
This reconfirms the positioning of the drug discovery support business as providing end-to-end support from exploratory basic research and drug discovery research through nonclinical and clinical trials. - FY2024-Q1RestatedAnnual report
「The Group operates end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies and clinical trials.」
This reconfirms the positioning of the drug discovery support business as providing end-to-end support from exploratory basic research and drug discovery research through nonclinical and clinical trials. - FY2023-Q3RestatedAnnual report
「This business provides end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies and clinical trials.」
This reconfirms the positioning of the drug discovery support business as providing end-to-end support from exploratory basic research and drug discovery research through nonclinical and clinical trials. - FY2023-Q2RestatedAnnual report
「This business provides end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies and clinical trials.」
This reconfirms the positioning as a drug discovery support business providing end-to-end support from exploratory basic research and drug discovery research through nonclinical and clinical trials. - FY2023-Q1RestatedAnnual report
「This business provides end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies and clinical trials.」
This reconfirms the positioning of the business as providing end-to-end support from exploratory research in drug discovery through nonclinical and clinical trials. - FY2022-Q3ReframedAnnual report
「This business provides end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies and clinical trials.」
Following the business transfer, the drug discovery support business is described as providing end-to-end services covering exploratory basic research and drug discovery research through nonclinical studies and clinical trials. - FY2022-Q2RestatedAnnual report
「This business provides end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through nonclinical studies, clinical trials and pathological diagnostics.」
This reconfirms the positioning as a drug discovery support business providing end-to-end support from exploratory basic research through nonclinical and clinical trials and pathological diagnostics. - FY2021RestatedAnnual report
「The Group's corporate philosophy is to contribute to the future and help realize the health and enriched lives of people worldwide. Its basic management policy is to achieve sustainable growth and enhance corporate value by aiming to become a unique, comprehensive drug discovery support company with strengths in every area from basic research to diagnostics.」
This reconfirms the corporate philosophy and basic policy of contributing to health, providing comprehensive drug discovery support from basic research through diagnostics, achieving sustainable growth and enhancing corporate value. - FY2021-Q3RestatedAnnual report
「The drug discovery support business provides end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through animal-based nonclinical studies, clinical trials and pathological diagnostics.」
This reconfirms the positioning as a drug discovery support company providing end-to-end support from exploratory basic research and drug discovery research through nonclinical and clinical trials and pathological diagnostics. - FY2021-Q1RestatedAnnual report
「We provide end-to-end services covering every stage of drug discovery, from exploratory basic research and drug discovery research in the initial stages through animal-based nonclinical studies, clinical trials and pathological diagnostics.」
This reconfirms the positioning as a drug discovery support company providing end-to-end support from exploratory research through nonclinical and clinical trials and pathological diagnostics. - FY2020RestatedAnnual report
「The Group's corporate philosophy is to contribute to the future and help realize the health and enriched lives of people worldwide. Its basic management policy is to achieve sustainable growth and enhance corporate value by aiming to become a unique, comprehensive drug discovery support company with strengths in every area from basic research to diagnostics.」
This reconfirms the philosophy and basic policy of contributing to health, providing comprehensive drug discovery support from basic research through diagnostics, achieving sustainable growth and enhancing corporate value. - FY2020-Q3RestatedAnnual report
「The Group's corporate philosophy is to contribute to the future and help realize the health and enriched lives of people worldwide. Based on this philosophy, the Group operates as a comprehensive drug discovery research support company through its genomics business, which provides genetically modified mice as tools mainly at the exploratory research stage of drug discovery; its advanced medicine business, which provides exploratory research support and conducts development research on candidate in vitro diagnostic agents; its CRO business, which evaluates drug discovery candidates; and its diagnostic business, which provides pathological diagnostics.」
This reconfirms the corporate philosophy and the basic positioning as a comprehensive drug discovery research support company in the basic policy for takeover defenses. - FY2019RestatedAnnual report
「The Group's corporate philosophy is to contribute to the future and help realize the health and enriched lives of people worldwide. Its basic management policy is to achieve sustainable growth and enhance corporate value by aiming to become a unique, comprehensive drug discovery support company with strengths in every area from basic research to diagnostics.」
This reconfirms the corporate philosophy and basic policy of contributing to health and providing comprehensive drug discovery support from basic research through diagnostics. - FY2019-Q2RestatedAnnual report
「The Group's corporate philosophy is to contribute to the future and help realize the health and enriched lives of people worldwide. Based mainly on this philosophy, the Group operates as a comprehensive drug discovery research support company through its CRO business, which provides tools such as genetically modified mice mainly at the exploratory research stage of drug discovery and evaluates drug discovery candidates through nonclinical and clinical trials; and its diagnostic analysis business, which provides exploratory research support, conducts development research on candidate in vitro diagnostic agents, and provides pathological diagnostics.」
This reconfirms the corporate philosophy and business positioning of operating CRO and diagnostic analysis businesses as a comprehensive drug discovery research support company. - FY2019-Q1RestatedAnnual report
「The Group's corporate philosophy is to contribute to the future and help realize the health and enriched lives of people worldwide. Based mainly on this philosophy, the Group operates as a comprehensive drug discovery research support company through its CRO business, which provides tools such as genetically modified mice mainly at the exploratory research stage of drug discovery and evaluates drug discovery candidates through nonclinical and clinical trials; and its diagnostic analysis business, which provides exploratory research support, conducts development research on candidate in vitro diagnostic agents, and provides pathological diagnostics.」
This reconfirms the positioning as a comprehensive drug discovery research support company through its CRO and diagnostic analysis businesses. - FY2018-Q3RestatedAnnual report
「The Group's corporate philosophy is to provide genetic information to basic research and medical and healthcare settings through the development of life resources ranging from biological organisms to genomes, contribute to their future, and help realize the health and enriched lives of people worldwide. Based on this philosophy, the Group operates as a comprehensive drug discovery research support company through its genomics business, which provides genetically modified mice as tools mainly at the exploratory research stage of drug discovery; its advanced medicine business, which provides exploratory research support and conducts development research on candidate in vitro diagnostic agents; its CRO business, which evaluates drug discovery candidates; and its diagnostic business, which provides pathological diagnostics.」
This restates the corporate philosophy and the basic positioning as a comprehensive drug discovery research support company through 4 businesses. - FY2018-Q2RestatedAnnual report
「The Group's corporate philosophy is to provide genetic information to basic research and medical and healthcare settings through the development of life resources ranging from biological organisms to genomes, contribute to their future, and help realize the health and enriched lives of people worldwide. Based on this philosophy, the Group operates as a comprehensive drug discovery research support company through its genomics business, which provides genetically modified mice as tools mainly at the exploratory research stage of drug discovery; its advanced medicine business, which provides exploratory research support and conducts development research on candidate in vitro diagnostic agents; its CRO business, which evaluates drug discovery candidates; and its diagnostic business, which provides pathological diagnostics.」
This restates the corporate philosophy and the positioning as a comprehensive drug discovery research support company comprising 4 businesses. - FY2018-Q1RestatedAnnual report
「The Group's corporate philosophy is to provide genetic information to basic research and medical and healthcare settings through the development of life resources ranging from biological organisms to genomes, contribute to their future, and help realize the health and enriched lives of people worldwide. Based on this philosophy, the Group operates as a comprehensive drug discovery research support company through its genomics business, which provides genetically modified mice as tools mainly at the exploratory research stage of drug discovery; its advanced medicine business, which provides exploratory research support and conducts development research on candidate in vitro diagnostic agents; its CRO business, which evaluates drug discovery candidates; and its diagnostic business, which provides pathological diagnostics.」
This restates the corporate philosophy and the basic positioning as a company providing comprehensive drug discovery research support through 4 businesses. - FY2017RestatedAnnual report
「The Group's corporate philosophy is to provide genetic information to basic research and medical and healthcare settings through the development of life resources ranging from biological organisms to genomes, contribute to their future, and help realize the health and enriched lives of people worldwide. Its basic management policy is to achieve sustainable growth and enhance corporate value by aiming to become a unique, comprehensive drug discovery support company with strengths in every area from basic research to diagnostics.」
This reconfirms the philosophy and basic policy of contributing to health through life resources and genetic information and providing comprehensive drug discovery support from basic research through diagnostics. - FY2017-Q3RestatedAnnual report
「The Group's corporate philosophy is to provide genetic information to basic research and medical and healthcare settings through the development of life resources ranging from biological organisms to genomes, contribute to their future, and help realize the health and enriched lives of people worldwide. Based on this philosophy, the Group operates as a comprehensive drug discovery research support company through its genomics business, which provides genetically modified mice as tools mainly at the exploratory research stage of drug discovery; its advanced medicine business, which provides exploratory research support and conducts development research on candidate in vitro diagnostic agents; its CRO business, which evaluates drug discovery candidates; and its diagnostic business, which provides pathological diagnostics.」
This restates the corporate philosophy and the basic positioning as a company providing comprehensive drug discovery research support through 4 businesses. - FY2017-Q2RestatedAnnual report
「The Group's corporate philosophy is to provide genetic information to basic research and medical and healthcare settings through the development of life resources ranging from biological organisms to genomes, contribute to their future, and help realize the health and enriched lives of people worldwide. Based on this philosophy, the Group operates as a comprehensive drug discovery research support company through its genomics business, which provides genetically modified mice as tools mainly at the exploratory research stage of drug discovery; its advanced medicine business, which provides exploratory research support and conducts development research on candidate in vitro diagnostic agents; its CRO business, which evaluates drug discovery candidates; and its diagnostic business, which provides pathological diagnostics.」
This restates the corporate philosophy and the basic positioning as a comprehensive drug discovery research support company spanning genomics, advanced medicine, CRO services and pathological diagnostics. - FY2016First statedAnnual report
「Through the development of life resources ranging from biological organisms to genomes, we provide genetic information to basic research and medical and healthcare settings, contribute to their future, and help realize the health and enriched lives of people worldwide.」
This sets out the basic philosophy of a company providing comprehensive support for drug discovery research through genomics, advanced medicine, CRO services and pathological diagnostics.